Johnson & Johnson says it has identified a lead vaccine candidate for the new coronavirus that it will develop in partnership with the US Biomedical Advanced Research and Development Authority (BARDA) J&J began developing the vaccine in January, as soon as the virusâ€™s sequence became available The firm says it and BARDA are willing to spend more than $1 billion to get the adenoviral vaccine into human clinical studies by September and available for emergency use in early 2021